These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28762128)

  • 1. Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products.
    Zou P; Tyner K; Raw A; Lee S
    AAPS J; 2017 Sep; 19(5):1359-1376. PubMed ID: 28762128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Core size determination and structural characterization of intravenous iron complexes by cryogenic transmission electron microscopy.
    Wu Y; Petrochenko P; Chen L; Wong SY; Absar M; Choi S; Zheng J
    Int J Pharm; 2016 May; 505(1-2):167-74. PubMed ID: 27001529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
    Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
    Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron sucrose: assessing the similarity between the originator drug and its intended copies.
    Di Francesco T; Philipp E; Borchard G
    Ann N Y Acad Sci; 2017 Nov; 1407(1):63-74. PubMed ID: 29168243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate.
    Brandis JEP; Kihn KC; Taraban MB; Schnorr J; Confer AM; Batelu S; Sun D; Rodriguez JD; Jiang W; Goldberg DP; Langguth P; Stemmler TL; Yu YB; Kane MA; Polli JE; Michel SLJ
    Mol Pharm; 2021 Apr; 18(4):1544-1557. PubMed ID: 33621099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferrous iron content of intravenous iron formulations.
    Gupta A; Pratt RD; Crumbliss AL
    Biometals; 2016 Jun; 29(3):411-5. PubMed ID: 26956439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose.
    Shah RB; Yang Y; Khan MA; Raw A; Yu LX; Faustino PJ
    Int J Pharm; 2014 Apr; 464(1-2):46-52. PubMed ID: 24440404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical and structural characterization of iron-sucrose formulations: a comparative study.
    Barot BS; Parejiya PB; Mehta DM; Shelat PK; Shah GB
    Pharm Dev Technol; 2014 Aug; 19(5):513-20. PubMed ID: 23701359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A robust and easily reproducible protocol for the determination of size and size distribution of iron sucrose using dynamic light scattering.
    Di Francesco T; Borchard G
    J Pharm Biomed Anal; 2018 Apr; 152():89-93. PubMed ID: 29414023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
    Jahn MR; Andreasen HB; Fütterer S; Nawroth T; Schünemann V; Kolb U; Hofmeister W; Muñoz M; Bock K; Meldal M; Langguth P
    Eur J Pharm Biopharm; 2011 Aug; 78(3):480-91. PubMed ID: 21439379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
    Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
    Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous iron.
    Auerbach M; Rodgers GM
    N Engl J Med; 2007 Jul; 357(1):93-4. PubMed ID: 17611217
    [No Abstract]   [Full Text] [Related]  

  • 13. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
    Auerbach M; Al Talib K
    Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.
    Wang C; Graham DJ; Kane RC; Xie D; Wernecke M; Levenson M; MaCurdy TE; Houstoun M; Ryan Q; Wong S; Mott K; Sheu TC; Limb S; Worrall C; Kelman JA; Reichman ME
    JAMA; 2015 Nov; 314(19):2062-8. PubMed ID: 26575062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral iron therapy options.
    Silverstein SB; Rodgers GM
    Am J Hematol; 2004 May; 76(1):74-8. PubMed ID: 15114602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Labile iron in parenteral iron formulations: a quantitative and comparative study.
    Van Wyck D; Anderson J; Johnson K
    Nephrol Dial Transplant; 2004 Mar; 19(3):561-5. PubMed ID: 14767009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicochemical properties of ferumoxytol, a new intravenous iron preparation.
    Balakrishnan VS; Rao M; Kausz AT; Brenner L; Pereira BJ; Frigo TB; Lewis JM
    Eur J Clin Invest; 2009 Jun; 39(6):489-96. PubMed ID: 19397688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parenteral iron use in the management of anemia in end-stage renal disease patients.
    Bailie GR; Johnson CA; Mason NA
    Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thermodynamic stability assessment of a colloidal iron drug product: sodium ferric gluconate.
    Yang Y; Shah RB; Faustino PJ; Raw A; Yu LX; Khan MA
    J Pharm Sci; 2010 Jan; 99(1):142-53. PubMed ID: 19492341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.